CONSUS Real Estate AG

  • WKN: A2DA41
  • ISIN: DE000A2DA414
  • Land: Deutschland

Nachricht vom 15.05.2018 | 05:57

CONSUS Real Estate AG: Divestment of commercial assets resulting in EUR 68.2 million cash inflow and significant profit

CONSUS Real Estate AG / Key word(s): Real Estate/Disposal
CONSUS Real Estate AG: Divestment of commercial assets resulting in EUR 68.2 million cash inflow and significant profit

15-May-2018 / 05:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Consus Real Estate AG ("CONSUS", ISIN DE000A2DA414), has signed definitive agreements to divest 8 commercial assets with a total gross asset value (GAV) of EUR 148 million to an institutional investor. The sale of the assets results in a preliminary significant profit and in net cash proceeds for CONSUS of around EUR 68.2 million. The corresponding run-rate net rental income of the divested assets is around EUR 10 million. The proceeds of the divestment will be used for general corporate purposes including reinvestment in the expansion of the development business.

Press Contact:
Peter Dietze-Felberg
Wallstrasse 16, D-10179 Berlin
+49 (0)30 28 44 987-62

CONSUS Real Estate AG
Andreas Steyer, COO and Head of IP/IR

Information and Explanation of the Issuer to this News:

About Consus Real Estate AG
CONSUS Real Estate AG ('CONSUS'), based in Berlin, Germany, is with its development branch CG Gruppe the leading rental housing developer in the country's nine largest cities. CONSUS focuses on and has a strong track record of institutional forward sales, digitalization and industrial mass production along the entire development value chain. The project development activities are supplemented by a high-yield proprietary portfolio of commercial real estate in Germany. The stock of Consus Real Estate AG is listed on m:access, the mid-market portal of Bayerische Börse, and is traded via XETRA in Frankfurt.

15-May-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

M1 Kliniken: Geschäftsjahr über den Erwartungen

Mit dem deutlichen Anstieg auf 21 Klinikstandorte (Ende 2016: 13) hat die auf ästhetische Medizin spezialisierte M1 Kliniken AG die Basis für einen Ausbau der Umsatz- und Ertragsbasis gelegt. Hinzu kommt die bereits in Umsetzung befindliche Erschließung weiterer Umsatzströme, wie etwa die Erweiterung der Eigenmarken oder die Abdeckung der ästhetischen Zahnmedizin. Das Kursziel beläuft sich auf 18,50 € und das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Q3-report 2018

18. Mai 2018

Aktuelle Research-Studie

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): BUY Valneva SE

22. Mai 2018